Currently, there are 55.71M common shares owned by the public and among those 50.08M shares have been available to trade.
Insiders at the company have transacted a total of 73 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 20 of these insider trades were purchases, accounting for 454,735 shares. Insider sales of the common stock occurred on 53 occasions, with total insider shares sold totaling 421,727 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 18.38, down -12.25%. The company’s stock has a 5-day price change of -20.50% and 21.81% over the past three months. AKRO shares are trading -23.94% year to date (YTD), with the 12-month market performance down to -62.97% lower. It has a 12-month low price of $11.25 and touched a high of $58.38 over the same period. AKRO has an average intraday trading volume of 1.02 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -19.86%, -16.04%, and -49.91% respectively.
Institutional ownership of Akero Therapeutics Inc (NASDAQ: AKRO) shares accounts for 103.23% of the company’s 55.71M shares outstanding.
It has a market capitalization of $989.41M and a beta (3y monthly) value of -0.44. The earnings-per-share (ttm) stands at -$2.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.87% over the week and 5.53% over the month.
Earnings per share for the fiscal year are expected to increase by 3.36%, and -26.06% over the next financial year.
Looking at the support for the AKRO, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on September 19, 2023, with the firm’s price target at $69.
